DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction

DiaMedica Therapeutics

DMAC

0.00

First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.